Impact of single-room contact precautions on hospital-acquisition and transmission of multidrug-resistant Escherichia coli: a prospective multicentre cohort study in haematological and oncological wards.


Journal

Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases
ISSN: 1469-0691
Titre abrégé: Clin Microbiol Infect
Pays: England
ID NLM: 9516420

Informations de publication

Date de publication:
Aug 2019
Historique:
received: 20 08 2018
revised: 15 12 2018
accepted: 23 12 2018
pubmed: 15 1 2019
medline: 22 11 2019
entrez: 15 1 2019
Statut: ppublish

Résumé

Colonization and infection with third-generation cephalosporin-resistant Escherichia coli (3GCR-EC) are frequent in haematological and oncological patients. In this high-risk setting, German guidelines recommend single-room contact precautions (SCP) for patients with 3GCR-EC that are non-susceptible to fluoroquinolones (F3GCR-EC). However, this recommendation is controversial, as evidence is limited. We performed a prospective, multicentre cohort study at four haematology and oncology departments assessing the impact of SCP on hospital-acquired colonization or bloodstream infection (BSI) with F3GCR-EC. Two sites performed SCP for F3GCR-EC patients including single rooms, gloves and gowns (SCP sites), and two did not (NCP sites). Active screening for 3GCR-EC was performed and isolates were characterized with molecular typing methods including whole genome sequencing and core genome multiple locus sequence typing to assess patient-to-patient transmission. Potential confounders were assessed by competing-risk regression analysis. Within 12 months, 1386 patients at NCP sites and 1582 patients at SCP sites were included. Hospital-acquisition of F3GCR-EC was observed in 22/1386 (1.59%) and 16/1582 (1.01%) patients, respectively (p 0.191). There were 3/1386 (0.22%) patients with BSI caused by F3GCR-EC at NCP sites and 4/1582 (0.25%) at SCP sites (p 1.000). Patient-to-patient transmission occurred in three cases at NCP and SCP sites each (p 1.000). The number of patients needed to screen in order to prevent one patient-to-patient transmission of F3GCR-EC was determined to be 3729. Use of SCP had no significant impact on hospital-acquisition or patient-to-patient transmission of F3GCR-EC in this high-risk setting.

Identifiants

pubmed: 30641228
pii: S1198-743X(18)30840-1
doi: 10.1016/j.cmi.2018.12.029
pii:
doi:

Types de publication

Journal Article Multicenter Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

1013-1020

Informations de copyright

Copyright © 2019 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All rights reserved.

Auteurs

L M Biehl (LM)

Department I of Internal Medicine, University Hospital of Cologne, Cologne, Germany; German Centre for Infection Research, Partner site Bonn-Cologne, Germany.

P Higgins (P)

German Centre for Infection Research, Partner site Bonn-Cologne, Germany; Institute for Medical Microbiology, Immunology and Hygiene, University of Cologne, Germany.

T Wille (T)

Institute for Medical Microbiology, Immunology and Hygiene, University of Cologne, Germany.

K Peter (K)

Department I of Internal Medicine, University Hospital of Cologne, Cologne, Germany.

A Hamprecht (A)

German Centre for Infection Research, Partner site Bonn-Cologne, Germany; Institute for Medical Microbiology, Immunology and Hygiene, University of Cologne, Germany.

S Peter (S)

Institute of Medical Microbiology and Hygiene, University of Tübingen, Tübingen, Germany; German Centre for Infection Research, Partner site Tübingen, Germany.

D Dörfel (D)

Department of Medical Oncology, Haematology, Immunology, Rheumatology and Pulmonology, University Hospital Tübingen, Tübingen, Germany; Clinical Collaboration Unit Translational Immunology, German Cancer Consortium (DKTK) and German Cancer Research Centre (DKFZ), Partner site Tübingen, Tübingen, Germany.

W Vogel (W)

Department of Medical Oncology, Haematology, Immunology, Rheumatology and Pulmonology, University Hospital Tübingen, Tübingen, Germany.

H Häfner (H)

Division of Infection Control and Infectious Diseases, Medical Faculty, RWTH Aachen University Hospital, Aachen, Germany.

S Lemmen (S)

Division of Infection Control and Infectious Diseases, Medical Faculty, RWTH Aachen University Hospital, Aachen, Germany.

J Panse (J)

Department of Haematology, Oncology, Haemostaseology, and Stem Cell Transplantation, Medical Faculty, RWTH Aachen University Hospital, Aachen, Germany.

H Rohde (H)

Institute for Medical Microbiology, Virology and Hygiene, University Medical Centre Hamburg-Eppendorf, Germany; German Centre for Infection Research, Partner site Hamburg-Lübeck-Borstel, Germany.

E-M Klupp (EM)

Institute for Medical Microbiology, Virology and Hygiene, University Medical Centre Hamburg-Eppendorf, Germany.

P Schafhausen (P)

Department of Oncology and Haematology, Hubertus Wald Tumorzentrum/University Cancer Centre Hamburg, University Medical Centre Hamburg-Eppendorf, Hamburg, Germany.

C Imirzalioglu (C)

Institute of Medical Microbiology, Justus-Liebig University, Giessen, Germany; German Centre for Infection Research (DZIF), Partner site Giessen-Marburg-Langen, Germany.

L Falgenhauer (L)

Institute of Medical Microbiology, Justus-Liebig University, Giessen, Germany; German Centre for Infection Research (DZIF), Partner site Giessen-Marburg-Langen, Germany.

J Salmanton-García (J)

Department I of Internal Medicine, University Hospital of Cologne, Cologne, Germany.

M Stecher (M)

Department I of Internal Medicine, University Hospital of Cologne, Cologne, Germany; German Centre for Infection Research, Partner site Bonn-Cologne, Germany.

J J Vehreschild (JJ)

Department I of Internal Medicine, University Hospital of Cologne, Cologne, Germany; German Centre for Infection Research, Partner site Bonn-Cologne, Germany.

H Seifert (H)

German Centre for Infection Research, Partner site Bonn-Cologne, Germany; Institute for Medical Microbiology, Immunology and Hygiene, University of Cologne, Germany.

M J G T Vehreschild (MJGT)

Department I of Internal Medicine, University Hospital of Cologne, Cologne, Germany; German Centre for Infection Research, Partner site Bonn-Cologne, Germany. Electronic address: Maria.vehreschild@uk-koeln.de.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH